Novartis Projects Slowed Growth Through 2031, Emphasizing Pipeline Potential Amid Patent Expiries
Trendline

Novartis Projects Slowed Growth Through 2031, Emphasizing Pipeline Potential Amid Patent Expiries

What's Happening? Novartis has projected a more modest average growth rate of mid-single digits through 2031, a slight reduction from previous analyst expectations. This outlook was shared during an investor day where the Swiss pharmaceutical company addressed the impact of generic competition and t
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.